3 Bullets: Adams-Oliver syndrome (AOS) is a rare congenital disease characterized by scalp lesions and limb defects. Additional vascular abnormalities and heart defects can lead to early death in some patients. By analyzing twelve families affected with the disease, we identified causal mutations in a new disease gene, NOTCH1, in five families. NOTCH1 is likely to be the major cause of AOS. NOTCH1 codes for a transcription factor that governs…
By Hsiao-Ching Chou LUXEMBOURG JOURNAL, June 12, 2013 – At the 17th-century Neumünster Abbey, the cultural heart of Luxembourg City, a small group of some of the world’s most cutting-edge scientists gathered on June 10-11, 2013, for a symposium to discuss the future of medicine and healthcare. The consensus was clear: Achieving the greatest advances requires “no-box” thinking, cross-disciplinary teamwork and, as ISB president, Dr. Lee Hood, likes to say,…
ISB is co-hosting a scientific symposium with Luxembourg Centre for Systems Biomedicine in Luxembourg City on June 10-11. Here are some scenes from Luxembourg pre-symposium. The full set of images can be found at this link: http://www.flickr.com/photos/90930918@N08/sets/72157634024779425/
Our Dr. Lee Hood is a guest mentor for The Wall Street Journal's Accelerators blog. In this post, he shares how nonprofit organizations can borrow the entrepreneurial and audacious-goal-oriented spirit of startups to be successful – in addition to remaining true to their missions. An excerpt: …achieving your vision requires determined optimism, the will to never give up, a missionary passion for the concept (to convince the skeptics), a willingness…
On Nov. 1, ISB and San Diego-based Sapphire Energy announced a strategic partnership to apply systems biology to algae with the goal of significantly increasing oil yield and improving resistance to crop predators and environmental factors in order to further the advancement of commercialized algae biofuel production. “Together, we have complementary expertise that will allow us to understand, reverse engineer and rationally alter the gene networks for fuel production in…
In May, ISB welcomed Dr. Robert Lipshutz as our Senior Vice President for Strategic Partnerships and Chief Business Officer. Rob came to us after having spent 19 years as an executive at Affymetrix, which develops genetic analysis technology. Rob has a PhD in mathematics and is looking forward to helping ISB expand our reach.
